Time for Cooperation in Health Economics among the Modelling Community

@article{Arnold2012TimeFC,
  title={Time for Cooperation in Health Economics among the Modelling Community},
  author={Ren{\'e}e Arnold and Sean Ekins},
  journal={PharmacoEconomics},
  year={2012},
  volume={28},
  pages={609-613}
}
1 Master of Public Health Program, Mount Sinai School of Medicine, Department of Preventive Medicine, New York, New York, USA 2 Arnold Consultancy and Technology LLC, New York, New York, USA 3 Arnold and Marie Schwartz College of Pharmacy, Brooklyn, New York, USA 4 Collaborations in Chemistry, Jenkintown, Pennsylvania, USA 5 Collaborative Drug Discovery, Burlingame, California, USA 6 Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland, USA 7 Department of… 
Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling
TLDR
In the recent NICE appraisals for rheumatoid arthritis the six companies involved each independently conducted systematic reviews, economic modelling and network meta-analyses, with multiple companies creating almost identical models.
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
TLDR
This paper discusses conflicting definitions of transparency in health economic modelling, and describes the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlights the challenges in its construction and maintenance.
Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals
Pharmacoeconomics is the discipline concerned with optimal allocation of resources to maximize population health from the use of medicines. Given that resources for health care are finite, economic
Model Registration: A Call to Action
TLDR
This editorial restate the call for a model registry and recommend actionable steps for its introduction and the landscape of academic publishing and collaboration has changed dramatically.
Pharmacoeconomics- Regulatory perspective and its relevance in Indian Context
TLDR
Pharmacoeconomic (PE) guidelines can be used as a standard for preparation of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study reports.
To model or not to model: lessons from two vaccinations
TLDR
Research is reported on the widespread use of modelling for two very different vaccinations human papillomavirus (HPV) and influenza in order to draw some lessons on behalf of health authorities.
Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics
TLDR
There is no consensus on how replicable models should be within health economics or what constitutes a successful replication, but replication studies can demonstrate how transparently a model is reported, identify potential calculation errors and inform future reporting practices.
Ahead of Our Time: Collaboration in Modeling Then and Now
TLDR
The time has come to truly embrace development of the registry of pharmacoeconomic models which was proposed 7 years ago and that the technology is certainly available to do this, as it was then.
Exploring the Feasibility of Comprehensive Uncertainty Assessment in Health Economic Modeling: A Case Study.
TLDR
Improvements in uncertainty assessment in general are no doubt desirable, and the development of detailed guidance and hands-on tutorials for methods of uncertainty assessment, in particular aspects of expert elicitation, evidence aggregation, and handling of structural uncertainty.
DISEASE PREVALANCE , PHARMACOECONOMIC STUDY AND PRESCRIPTION PATTERN STUDY IN PEDIATRIC PATIENTS
Introduction: Paediatrics is the branch of medicine which deals with the development, growth, diseases and disorders in children. Materials and Methods: Our research as a prospective observational
...
1
2
3
...

References

SHOWING 1-10 OF 43 REFERENCES
Methods for the economic evaluation of health care programmes, 3rd ed
TLDR
The “blue book” systematises and summarises recent knowledge on the main types of economic evaluations, thereby providing a useful overview including sources of further readings.
Drug discovery dilemma and Cura quartet collaboration.
TLDR
A group of prominent scientists from the academic, industry, government and disease advocacy communities came together to discuss new paths forward for stronger inter-institutional collaboration to establish a framework for translating new discoveries into drugs, improving proof of concept (PoC) studies, and reducing attrition at the clinical stage of drug development.
Methods for the economic evaluation of health care programmes
TLDR
Using archival material supplemented by interviews with community physicians, Jane Lewis shows how 'public health' and 'preventive medicine' have been supplanted as the central concern of medicine by curative and acute specialties.
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
  • M. Weinstein, B. O'brien, +4 authors B. Luce
  • Computer Science, Medicine
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2003
TLDR
It is the responsibility of model developers to conduct modeling studies according to the best practicable standards of quality and to communicate results with adequate disclosure of assumptions and with the caveat that conclusions are conditional upon the assumptions and data on which the model is built.
Pharmacoeconomics : From Theory to Practice
TLDR
This chapter discusses the use of Pharmacoeconomics in Drug Reimbursement in Australia, Canada, and the United Kingdom and some problems/Assumptions in Pharmacoeconomic Analysis.
How Can Cost-Effectiveness Information Help Control Unsustainable Growth in U.S. Health Care Spending?
TLDR
There is clearly a difference of opinion as to whether the production of comparative effectiveness and cost-effectiveness information should lie within the scope of a single entity or more than one, but this disagreement should in no way weaken the College's position that cost is important, that its use must be transparent, and that cost should never be compared without simultaneously considering comparative clinical effectiveness.
The pharmaco-economics of peri-operative beta-blocker and statin therapy in South Africa.
TLDR
It is shown that acute peri-operative beta-blockade and statin therapy could result in a cost saving through a reduction in major perioperative cardiovascular complications in patients with an expected per-operative major cardiovascular complication rate exceeding 10% following elective major non-cardiac surgery.
To model or not to model: lessons from two vaccinations
TLDR
Research is reported on the widespread use of modelling for two very different vaccinations human papillomavirus (HPV) and influenza in order to draw some lessons on behalf of health authorities.
Cost-effectiveness analysis: should it be required for drug registration and beyond?
TLDR
In this era of finite budgets, CEA may facilitate drug development, drug approval, patient segmentation and pricing model development throughout the drug lifecycle continuum.
Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
TLDR
Pravastatin therapy was more cost-effective among older than younger patients, because of their higher baseline risk and greater cost offsets, despite their shorter life expectancy.
...
1
2
3
4
5
...